Merck's PCSK9 Pill Shows Promise in Lowering Cholesterol to Injectable Levels
TL;DR Summary
Merck has developed a new pill called enlicitide that significantly reduces LDL cholesterol levels by blocking the PCSK9 protein, showing promising results in clinical trials with a 20% reduction in heart attack and stroke rates among high-risk patients, and offering a potentially more affordable alternative to existing injectable treatments.
- Merck PCSK9 Pill Results Point to Extremely Low Cholesterol Future The New York Times
- Experimental daily pill may lower cholesterol in patients who don’t see enough benefit with statins alone, study finds CNN
- Merck’s pill to reduce cholesterol on top of statins matches results from injectables statnews.com
- Oral PCSK9 Inhibitor Enlicitide Matches Injectables in Lowering LDL Cholesterol AJMC
- Investigational daily pill lowered bad cholesterol as much as injectables www.heart.org
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
2 min
vs 3 min read
Condensed
89%
428 → 49 words
Want the full story? Read the original article
Read on The New York Times